How to Cite:
Kumar, M., Kumar, P., Sagar, S., & Chaudhary, A. (2022). Iron oxide nanoparticles approaching to eradicate her2-positive breast cancer: A review. *International Journal of Health Sciences*, *6*(S2), 12680–12707. https://doi.org/10.53730/ijhs.v6nS2.8308

Iron oxide nano particles approaching to eradicate her2-positive breast cancer: A review

Mudit Kumar
Assistant Professor, Faculty of Pharmacy, Uttar Pradesh University of Medical Sciences Saifai, Etawah U.P.India

Dr. Pushpendra Kumar
Assistant Professor, Faculty of Pharmacy, Uttar Pradesh University of Medical Sciences Saifai, Etawah U.P.India
Corresponding author email: pushydv15@gmail.com

Sakshi Sagar
Assistant Professor, Department of Pharmacy, J.S.University Shikohabad, Firozabad, U.P., India

Atul Chaudhary
Department of Research and Development, Simplex Pharma Pvt.Ltd., Kotdwar, Uttrakhand, India.

***Abstract*---**Background: Breast cancer is the second foremostreason for death in femalesuniversal. The enormously fast level of metastasis and capability to growconfrontationmethods to all the unoriginalmedications make them self-sameproblematic to indulgence which the reasons for in elevation morbidity and mortality are of breast melanoma patients. Expertsall through the world have been directing on the firstdiscovery of breast lump so that conduct can be started at the very primary stage. Furthermore, conventional treatment methods such as chemotherapy, radiotherapy, and local surgical treatmentsmart from innumerablerestrictions including toxicity, genetic mutation of normal cells, and spreading of cancer cells to healthy tissues. Therefore, new treatment schedules with low toxicity to usual cells need to be immediatelyadvanced. Methods: Iron oxide nanoparticles have remainedextensively used for targeting hyperthermia and imaging of breast growth cells. They can be conjugated with drugs, proteins, enzymes, antibodies, or nucleotides to bring them to target organs, tissues, or tumors using an external magnetic field. Results: Iron oxide nanoparticles have remainedpositively used as theranosticscauses for breast malignancy both in vitro and in vivo. Besides, their functions with medications or functional biomolecules increase their drug delivery efficiency and

Manuscript submitted: 09 March 2022, Manuscript revised: 18 April 2022, Accepted for publication: 27 May 2022

decrease the systemic noxiousness of drugs. Conclusion: This appraisalmostlyemphasizing on the multipurposepresentations of superparamagnetic iron oxide nanoparticles on the analysis, behavior, and perceiving progress of breast diseasecure. Their extensiveuse is since of their outstandingsuperparamagnetic, biocompatible, and biodegradable properties.

***Keywords*---**iron oxide nanoparticles, breast cancer, hyperthermia, photothermal therapy, MRI contrast agent, theranostics.

Introduction

Overall disease numbers demonstrated that in malice of numerousnovel and advanced plans advanced for activediscovery andconduct of numerousgrowths, the occurrence of cancer hasenlargeduniversal[1]. Amid numerous tumors identifiedand pickled, breast malignancy is the 5th important cause for malignancydeaths[2]. In India, breast tumor is the bestusuallyidentifiedcancer (21%) and single of the fatal cancers (21%)[3]. Thesefacts are expected to rise in the yet to come, thusaggregate the problem of this frightfulinfectionadvance. In recent times, the practice of nanoparticles (NPs) in cancer treatment is gaining fame[4]. NP's as of their major size (1–100 nm) attitudesubstantialextents resulting in conversion in center energies and other things[5]. So, they showsole optical, electronic, photochemical, magnetic and chemical properties which can be used variously for use in tumortreatment, When a substancemeasurable is complete into NPs, here is a bigsurge in surface area and then, a greatnumber of surface atoms are uncovered to connections with extra molecules[6].They are so more sensitive than at the macroscopicscale. NP shells can be close with several molecules likechemical compounds, medicines, and proteins by covalent bondsor by absorption[7]. This aids in the targeted delivery of NP-taggedmolecule/complexes to cancer soft tissue. Inactive targeting ofsarcoma tissues can also be reached due to their lesser size and enhanced permeability and retention (EPR) effect[8, 9]. Accordingly,divergent to straight and clinically agreedmethodologies to cancer treatment, NPs can exactly target (passively or actively) lumpssubsequent in abridged/little side effects and toxicities. They can also avoid p-glycoprotein connected drug resistance devices leading to restored efficacy[10].

Anatomy of the adult female breast

The mature feminine breast is predominately collected of glandular lobules, milk ducts, adipose, connective tissues, and skin[11]. Mature feminine breast structure appearance (figure 1).The glandular lobules and milk ducts—frequently raised to as fibro glandular tissue—are enclosed by thick connective tissues that preserve the breast integrity[12]. Every one breast is close to the chest by the pectoral fascia over the pectoralis major muscles, but its shape is recognized and continued by the skin[13]. The breast adjustments below hormonal influence and due to the elderly. For illustration, the ductal and glandular structure surges in size through the scheduled premenstrual phase—opposing to the postmenstrual phase—while adipose is existence almost completely exchanged by ductal and glandular tissue during pregnancy[14, 15]. When menopause occurs, fibro glandular tissues shrink, and fat changes to prime. Understandably, due to these discrepancies, breast tissue biomechanics are credible to change[16].

Each one breast has 15 to 20 units, or lobes, that border the nipple in a radial manner, like shafts on a wheel. Intimate these lobes are smaller sections, called lobules. At the finale of both lobules are tiny "bulbs" that produce milk. These buildings are connected by small tubes called ducts, which convey milk to the nipples. Fat fills the places between the lobes and ducts. The nipple is in the middle of a dark area of skin called the areola[17]. The areola contains smallglands that grease the nipple during breastfeeding. There are certainly not muscles in the breasts, but muscles grey lies under each breast to shield the ribs[18].

Pathophysiology of breast cancer

The recent appreciative of breast cancer etiopathogenesis is that aggressive cancers grow up through a sequence of molecular changes at the cell level. These variations affect in breast epithelial cells with memorable structures and unrestrained growth[19]. Genomic outlining has recognized the occurrence of isolated breast tumor subtype with separate natural histories and clinical behavior. The rigorous amount of disease subtype and molecular variations from which these subtypes get up residues to remain fully elucidated, nonetheless these normally align with the presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER 2)[20, 21]

Breast cancer is malicious cancer that surprises in the cells of the breast. Like further cancers, here are several factors that can increase the risk of receiving breast cancer. Impairment to the DNA and genetic mutations can lead to breast cancer want existed experimentally related to estrogen exposure[22]. Some characters inherit defects in the DNA and genes like the BRCA1, BRCA2, and P53 between others. Those with a family history of ovarian or breast cancer so remain at a better risk of breast cancer[23]. (figure 2)

The immune arrangement normally looks designed for cancer cells and cells with injured DNA and abolishes them. Breast tumors may be a sign of failure of such a real immune defense and investigation[24]. These are several signing schemes of growth factors and other mediators that transmit between stromal cells and epithelial cells. Disorderly these can lead to breast malignancy as well[25].

Iron oxide Nanoparticles (NPs)

IONPs opinion out amongstnumerous other NPs since of their low price, superparamagnetic behavior, biocompatibility, andbiodegradability[26]. They have expandedenormoussignificancein the pitch of cancer treatment because of their superparamagneticproperty, by the feature of which they can warmness up whenvisible to an external magnetic field or can be modestlyledto a target site using a peripheral magnet[27]. IONPs are moreover themerely metal oxide NPs permitted for use in MRI. Superparamagnetic iron oxide nanoparticles

(SPIONPs)have many magnetic stages, of which magnetite (Fe_3O_4)and maghemite (γ-Fe_2O_3) are chieflytalented in biomedicine. For instance, in MRI, measured renal clearanceand higher relaxation standards of SPIONPs likened tothe predictablycastoff contrast agents like gadolinium-basedcontrast agents, make them more eye-catching for imaging purposes.Feridex, endorem, combidex and sinerem are certainclinically accepted SPIONPs for use in MRI SPIONPs can also be simplyembattled to lumpskinsby using anexternal magnetic field. SPIONPs also bargainhabit in other biomedicaluses like tissue detailedstatement of therapeutic agents,enrichment of imaging and detection in MRI, hyperthermiacreated killing of cancerous cells, radio sensitization, magneticfield aided radionuclide therapy, and in *in vitro* diagnostics asmagnetic sensing reviews. They can be used for eliminatingcontaminants from milled water, nutritional supplementationof iron in the diet as well for curing anemia, hemoglobin guideline, and as Nano adjuvant for preparation and antibody production[28],(figure 3).The topportionaround using SPIONPs in tumortreatment is that they get corrupted and absorbed by the formand hence do not collect in the body. IONPs can be hastened in Nano domains of water precipitationsdetached in an oil stage by microemulsion technique. Theycan also be synthesized electrochemically by electrolysisanywhere iron anode is hastened as IONPs in the electrolyte.Auditory cavitation produced by ultrasound is also helpful forthe production of IONPs. In laser paralysis, vapors of iron predecessorsare excitedtrailed by skillfulcorrosion to getIONPs.

Numerousorganiccreatures from bacteria toplants have also remained used for the production of IONPs. For factsof the means of production of IONPs, getin another place[29].Thoughtful the connectionamongst the magnetic propertiesand the magnitude and outline of IONPs is a qualification forcommontenders of charm in numbersloading andbio-separation areas. Usually, α-Fe_2O_3 has feeble ferromagnetismat room temperature, though the inundation magnetizationis often lesser than 1 emu g^{-1}. Though, γ-$Fe_2O_3$and Fe_3O_4 show ferrimagnetism at room temperature, usingthe saturation magnetization realization to 92 emu g^{-1}. It isnotable that severalpossessions of IONPs be determined by theirsize and shape[30]. For sample, Levy et al deliberate the magneticproperties of IONPs from 6 to 18 nm, the outcomesexposed thathypnotic disorder was mainlyobvious for 13–18 nmIONPs owing to a severe loss of their hyperthermia performance. Guardia et al described that pseudo-sphere-shaped and facetedIONPs with a contracted size distribution (4–20 nm) and a in elevation saturation magnetization ($M_s \approx 80$–85 emu g^{-1} at 5 K) weregained by currentputrefaction using oleic acid as asurfactant. In disparity, decanoic acid vintagesfar larger pseudo cubic IONPs (45 nm) with bigger size disseminationand larger saturation magnetization (Ms. = 92 emu g^{-1} at energy can dazing the anisotropy vitalitywall of asolitary nanoparticle. Though, accumulationbetween superparamagneticIONPs is a mutual phenomenon. Henceforth, fordefensiveplain IONPs alongside aggregation, the charmingassets can be tailored by the coating materials, such asAu, Ag, and $Co_3O_4$5 K), which is close to the predictable value for bulk magnetite. Basic iron oxide nanostructures are verytempting, owed to their numerousexclusive physicochemicalproperties founded on high essential anisotropy and externalactivity[31]. Newly, we displayed a proportionalrevision of themagnetic comportment of only and tubular clustered Fe_3O_4 NPs[32].The gradesdiscovered that the war of the demagnetizationenergy of profile and the magneto crystalline anisotropyenergy of unimportant IONPs would surge the coercivity and themagnetic properties are strappinglyunfair by the morphologyof the Fe_3O_4 NPs[33]. overall, IONPs developsuperparamagnetic at room temperature once the size ofIONPs is under about 15 nm, the sense that the thermal energy can overcome the anisotropy energy wall of a single nanoparticle[34]. Though, accumulationbetween superparamagneticIONPs is a common phenomenon. Later, for caringbasic IONPs against collection, the magnetic properties can be personalized by the coating materials, such as Au, Ag, and Co_3O_4.Magnetic iron oxide nanoparticles with a plain surface be likely to agglomerate for the reason that of tough magnetic attractions between the particles; therefore, stabilizers such as carboxylates, inorganic compounds, and polymeric mixtures are frequently used to increase the solidity of the nanoparticles in suspension[35, 36].(Shown in the figure. 4)

Iron Oxide used in Breast Cancer Therapy

Although various growths in the behavior and identification of breast tumors, stay in diagnosis brands it immobile one of the deadliest cancers[37]. Conservativeactionmethods include hormone therapy, immunotherapy, chemotherapy, etc.[38]. Cancer immunotherapy contains the practice of antibodies which fix to receptors and incapacitate breast melanoma cell growth signaling pathways[39]. Marketable use of trastuzumab antibodies compared to human epidermal growth factor receptor 2 (Her2) is a simple sample of popular use of tumor immunotherapy[40]. In hormone analysis, breast melanoma growth stimulating hormone, estrogen, is depressed in the body, or estrogen receptors (ER) are choked[41]. For instance, estrogen similarity tamoxifen (TMX) is used to block estrogen from mandatory to ER and initiate estrogen approachableDNAs that stimulate breast malignancy cell growth[41].Both overheadrevealedanalyses can nevertheless be used only in the situation of breast disease cells stating estrogen, progesterone, or Her2 receptors. Though breast cancer cells communicatingnothing of these receptors i.e. triple-negative (TN) breast tumor cells are very violent and hard to treat[42]. Chemotherapy has remained used to delight TN breast malignancy, which consumesgrave side effects owing to non-specificity. Conversely, owing to the numerouslimits and side effects related to these treatments, different treatment approaches are existenceestablished[43]. NPs in breast tumor therapy are viewinghopefulupshots[44].(figure 5)

Academic contents

a) Susann Pichler et al prepared: Iron Oxide Nanoparticles as Carriers for Doxorubicin and Magnetic Hyperthermia after Intratumoral Application into Breast Cancer in Mice. (Received: 2 April 2020; Accepted: 21 May 2020; Published: 26 May 2020)

In this article, researcher loaded doxorubicin (DOX) induced magnetic nanoparticles (MNPs) and examined against tumor activity in cancerous cell of breast (BT474) in the effect of magnetic hyperthermia (43°C, 1h). The writer says-

1. Intratumoral implementation of doxorubicin-loaded magnetic nanoparticle (at minimum concentration of 9.6 nmol DOX/100 mm^3 tumor value)

associated with agentic hyperthermia favors tumor cell death in vivo, and that there is scientific proof of an impacts positively compared with magnetic hyperthermia alone or free Doxorubicin implementation intratumoral.

2. The involvement of the pseudopeptide NucAnt (N6L) on the magnetic Nanoparticles surface might well be advantageous in its role as a messenger for the internalization of magnetic Nanomaterials in to in vitro breast cancer cells, which will further increase the likelihood of subsequent activation of intracellular heating sports and cell death.

b) Shengzhe Zhao et al prepared, multipurpose nanoparticles made from magneto strictive iron oxide: a highly developed framework for cancer theranostics. (Received: 2019.11.29; Accepted: 2020.04.27; Published 2020.05.15)

Multipurpose magnetic nanoparticles and related nanostructured materials have provoked considerable attention in recent years about multi-mode imaging and synergistic treatment for cancer in this paper, prepared by scientists. Because of its intrinsic magnetic resonance imaging (MRI), biocatalytic activity (nanozyme), magnetic hyperthermia therapy (MHT), photo-responsive therapy and therapeutic agents for chemotherapy and genetic modification, operational magnetic iron oxide nanoparticles (Fe3o4 NPs) have also shown great promise as an advanced platform.

Thermotherapy (hyperthermia)

Hyperthermia is unique to the numerous treatment modalities usedin cancer healing[45]. It is rummage-sale to kill prison cell by baring them to higher temperatures ranging from 41 °C to 46 °C. SPIONPs inserted into the lumpskins can be passionate aboutconsuming an external magnetic field. In the existence of the magneticfield, the SPIONPs fright to pulse and generate heat,which in opportunityhires the cancer cells. IONPs must berecycledto kill tumor cells by hyperthermia unaccompanied or in mixturewith drugs which is deliberated in groupingtreatments.Table 1accumulates the books on the usage of IONPs in killing breast tumor cells by cooking them up to hyperthermia temperatures[46, 47].

Combination therapy

IONPs in accumulation to treatments can also carry a variability of particlesto act as multifunctional Nanocarriers[48, 49]. IONPs must berecycled to kill malignancy cells by a combinatorial methodof hyperthermia and chemotherapy (drugs such as cinnamaldehyde,selol, DOX, alendronate, Docetaxel, etc.). The leadof consumingmishmash is that greater toxicity is perceivedat dosageslesser than in these treatments alone, hencedecreasingside effects[50, 51].

Cinnamaldehyde marked IONPs concentrated the possibility of breast cancer cell lines (MCF-7 and MDA-MB-231) atamountsinferior to free cinnamaldehyde and might heat up to hyperthermia temperatures. Cinnamaldehyde-IONPs canconsequently be used to improvethe killing of tumor cells finished a combined method of hyperthermia and a lesser therapeutic dose of the drug, subsequent in summarynoxiousness to normal cells[52]. Also, Selol-IONP nanocomplexes were started to be added cytotoxic than free ledge to neoplastic breast cell lines (4T1 and MCF-7) Nanocomplexes such as DOX-IONP and alendronate-SPIONPs were also extraoperative in homicideMDA-MB-231 breast tumor cells using a combinatorial methodology of chemotherapy and hyperthermia than hyperthermia or drug only[53, 54]. Thesenanocomplexes remained able to decrease the cancer growth in stripped mice bearing MDA-MB-231 growths compared to free drug[55].They had important superparamagnetic properties to be recycled in MRI[56].IONPs conjugated to radiopharmaceutical agent lutetium-trastuzumab, have tobe sited used for the doublepersistence of radio immunotherapy(RIT) for action, and approximation of the amount of therapeutics brought to cancers and serioustissues using by MRI[57, 58]. lutetium-trastuzumab IONPs or Lu-trastuzumab-NPs inoculated into breast cancerdemeanor BALB/c mice mightsuccessfullycumulative in the liver with no explicitgathering in other organs. Because ofgreatsympathyfor the IONP composite in MRI, liver and cancermovementvaluationsutilizing MRI images were also close to actualtotals of therapeutics specified[59, 60].

Synthesis methods of magnetic IONPs

At that period, a diversity of artificialways such as co-precipitation, thermal decomposition, hydrothermal and solvothermal syntheses, sol–gel synthesis, microemulsion,ultrasound irradiation, and biological synthesis mustbe thereuseful to yield magnetic IONPs[61, 62].(figure 6)These approaches can beseparated into aqueous and non-aqueous routes[63]. Aqueous approaches are smart in terms of their squat cost and sustainability, but, a generic task in openlylocating water-soluble monodisperse magnetic IONPs deprived of size collection. [64, 65]. Numerous magnetic nanostructures with dissimilar morphologies have been produced, including particles, wires, and rods[66].

Methods of synthesis of iron oxide nanoparticles

The description of the overheadstatedartificialapproaches are momentarilyconcise. table 2. In the relation of effortlessnessof fusion, typical co-precipitation is the favoriteroute[67]. In standings of size and morphology control of IONPs,thermal decomposition looks as if the bestprocess to changeIONPs slighter than 20 nm, and the hydrothermal or solvothermalprocesslooks to be the maximumappropriate for makingIONPs larger than 20 nm[68, 69]. As another, furtherdevicescan moreover be used to synthesize magnetic IONPs with slightsize distribution and well-regulated morphology[70].Nevertheless, themost importantcomplications in the synthesis of IONPs are immobile to switchthe size, shape, composition, and size distribution on thenanoscale because of the point that the accumulation and/or unceasingdevelopment of IONPs to diminish the complete surface freeenergy and magnetic interactions. The recentapproachesregularlyinclude the amount of dissimilarstages with manifoldmicro structuralproblems that might have a maliciouseffect onthe magnetic enactment[71].

Surface functionalization of magnetic IONPs

An inescapabledifficultattendant with alluring IONPs in the dimensionarray is their centralvolatility over lengthierphases, which exhibits in two main ways[72]:

1. Damage of dispersibility, where minor NPs incline to combined and form greatunits to decrease the superficialdynamism.(figure 9)
2. Damage of magnetism, where bare IONPs are simplyrusty in airborneowed to their high chemical action, especially Fe3O4 and γ-Fe2O3 NPs.

So, it is vital to growing a suitablesecurityplan to chemically stabilize simple IONPs against harm all through or after the following application[73]. For biomedicaluses, it is essential to get water-dispersible NPs,since most living media are almost neutral aqueoussolutions[74].(figure 7)In the interpretation of the various strategies and their ensuingapplication, determinationsrequire to fanatical to formulating fourcategories of IONP-based materials, comprising the central–shellstructure, matrix discrete structure, Janus-type heterostructures, and shell–central–shell structure[75, 76].(figure 8)

Coating Material of Iron Oxide Nanoparticles (Synthetic and natural Polymer)

Drugs Bounds to IONPs

Magnetic nanoparticles have superiorresponsivepart and facility to cantankerousorganic barriers than their micrometric complements, which special treatment their usage in medicationtransfermethods[77]. In this framework, dissimilarlessons of medications can be directly assured to IONPs or core-shell nano systems[78]. as shown in Figure 10. Such requisite can happen by adsorption, diffusion in the polymer matrix, encapsulation in the center, electrostatic interactions, and covalent attachment to the surface, directing to advance their pharmacological properties[79, 80]. IONPs have stayedrummage-sale as carriers of anticancer, alternative, immunosuppressive, anticonvulsant, anti-inflammatory, antibiotic, and antifungal agents[81, 82].

1. Anticancer Drugs: One of the chiefexperiments in cancer usage is the leniencesettledduring the remedy, which diminishesreaction to the medicine[83]. As soon as a drug is assured to IONPs, this acceptance can be dazedowed to a decrease of the "efflux pumps" that transport the drug to the exterior of the cell, whateverat laststimulatesproliferation in drug concentration in carcinogenicsoft tissue[84, 85]. IONPs-based Nanocarriers are also capable to shrink undesired relations with other fragments. and lethal effects on common tissues. Moreover, these nano systems are a smaller numberof specificmolecules such as antibodies and peptides, therefore acting on many types of melanoma[86, 87].
2. Immunosuppressive: In elevation concentrations of immunosuppressants may producesevere secondary worries in patients with transfers or autoimmune diseases[88]. To diminish this difficulty, a nano systempoised by silica (SI)-coated IONPs was expressed to turn as a carrier of mycophenolic acid (MPA), the corepart of the immunosuppressive

mycophenolate mofetil[89, 90]. MPA was destined to the SI-coated IONPs by resources of hydrophobic interfaces, and the causingnano systems werebiocompatible at the concentration of 0.56 mg/L, with the capability of shipping up to 30% of MPA's weight. At this meditation, the IONPs-SI-MPA nano systems werecapable to shrink the excretion of human interleukin 2 and lump necrosis factor-α, specifying the stimulus of immune cells. Even though the 10-fold lower MPA stream when equaled to other revisions, this nano systemsstimulated a similar value in cytokine up-regulation[91].

3. Anticonvulsants: Nanotechnology has also caused a unique and non-invasive methodfor the dealing of sequential lobe epilepsy associated with pharmacological resistance[92]. A nano systempoised by anti-interleukin-(IL)-1β monoclonal antibody (1-β mAb) covalently involved to IONPs functionalized with PEG was established and inserted into the caudal vein of rats with acute temporal lobe-induced epilepsy[93, 94].
4. Antibiotics:The appearance of extremely resistant bacterial straining and the cheapsubstitutes to conservative antibiotics has stimulatednotice in the plan of antibiotic-carrier nano systems[95]. IONPs functionalized with CS needto be located used as carriers of streptomycin. As a physical mixture, this antibiotic presented a rapid release (20 min) in phosphate-buffered saline, though in the procedure of a nano systems its filledissue was finalized only after 350 min, representing the facility of IONPs to act in controlled-release systems[96, 97].
5. Antifungal: Fungal diseases are adaptable infections that regularlyupset immunocompromised patients and, if not correctlycured, can be lethal[98]. Subsequently, Nystatin (NYS) is one of the most frequently used fungicides, Hussein-Al-Ali et al. prepared a nano systemserene by IONPs, CS, and NYS. The writtersproved that the publicationoutline of NYS in a somatic mixture of these insulatedcomposites lasted about 20 min, compared to 1800 min of the IONPs-CS-NYS nano systems. This metamorphosiscan be illuminated by the electrostatic collaboration between NYS (negatively charged) and CS (positively charged), by which it can be incidental that the IONPs-CS-NYS nano systems was talented to produce a controlled release of NYS[99]. Ketoconazole and amphotericin B are additional antifungal drugs that must beverified in the growth of magnetic nano systems in instruction to reduction their side effects and recover antifungal action. Ketoconazole was joined to epoxy-functionalized IONPs powerless with HSA, and its compulsorydevicehappened via hydrophobic contact, while amphotericin B was directly bound to IONPs by a response between amine and aldehyde groups, individually from the antifungal drug and IONPs.

Application & Biomedical applications of IONPs

Magnetite and maghemiteare desired in biomedicine since they are biocompatible and possibly non-toxic tohumans[100]. Iron oxide is simply degradable and then valuable for in vivo applications .Outcomes from the revelation of a hominid mesothelium cell line and a murine fibroblast cell line to seven technologically essential nanoparticles indicated a nanoparticle definite cytotoxic machinery for uncoated iron oxide. Solubility was initiate to strongly guidance the cytotoxic answer[101]. Labeling cells (e.g. stem cells, dendritic cells)with iron oxide nanoparticles is an exciting new device to monitor such labeled cells inreal-time by magnetic resonance tomography. Iron oxide nanoparticles are jumble-sale in cancer magnetic nano therapy that is founded on the magneto-spin belongings in free-radical reactions and semiconductor measurable capacity to generate oxygen radicals, furthermore, control oxidative stress in biological means underneath in regular electromagnetic radiation. The magnetic nano therapy is tenuously measured by external electromagnetic field reactive oxygen species (ROS) and reactive nitrogen species (RNS)-mediated resident toxicity in the lumps during chemotherapy with antitumor magnetic composite and minor adjacent possessions in regular tissues[100, 102]. Magnetic facilities with magnetic recall that comprise of iron oxide nanoparticles overburdened with antitumor drug have further benefits over predictable antitumor drugs owing to their capability to be at all measured through targeting with an endless magnetic field and additional support of their antitumor action by sensible inductive hyperthermia (below 40 °C). The collective inspiration of in similar constant magnetic and electromagnetic fields during nano therapy has started splitting of electron energy levels in magnetic complex and unpaired electron transfer from iron oxide nanoparticles to anticancer drug and tumor cells[103]. In actual, anthracycline antitumor antibiotic doxorubicin, the native state of which is diamagnetic, obtains the magnetic properties of paramagnetic substances.

Iron oxide nanoparticles might be used in magnetic hyperthermia as a cancer treatment method[104]. In this technique, the Ferro fluid which comprises iron oxide is vaccinated tocancer and then intense up by a blinking high incidence magnetic field. The temperature
spreading shaped by this heat generation may assistance to finish cancerous cells intimate
the growth[105].

Mechanism of action of IONPs

a. Iron overload and induction of reactive oxygen species(ROS)magnetically targeted IONPs gather in the targeted tissueswhich can clue to iron overkill and thus discrepancy iniron homeostasis. The spare iron ions central to the overproductionof ROS which is poisonous to the cells[106]. IONPs once affected by the cells go in the lysosomeswherever they are fragmented down in the acidic atmosphere intofree iron ions. These iron ions are then merged in the body in the practice of proteins like ferritin, haemoseridian, etc. Spare free iron ions engenderROS by sharing in The Haber–Weiss reaction and Fenton reaction. The improvedROSinventionmakes oxidative stress. Thesefallouts in DNA damage, oxidative stress, epigenetic events,inflammatory procedures, and cytotoxicity[107]. Free iron ions finished Fenton reaction must bedescribed to effectupgrade of tumor from stage-I to stage-II in murine skin. IONPs have been originating to reduction cell practicality, improved lactate dehydrogenateleak, ROS, and lactoperoxidase planes and exhausted glutathione, superoxide dismutase, and catalase in absorption and the time-dependent way in human breast cancer cells (MCF-7). Induction of ROS by IONPs and cell death has also been described in numerousfurtherlessons[108].

b. Hyperthermia: IONPs can destroy the melanoma cells by hyperthermia likewise. IONPssince of the superparamagnetic goods can be magneticallybattered to the tumor sites or straight injected into thetumor tissues. These added IONPs when exposed to afluctuating magnetic field, absorb the energy, start to vibrate, and then convert them into heat energy. The heat engendered by the IONPs is significantly high (above 42 °C) and soterminates the tumor cells[109]. The benefit of using IONPs in hyperthermia is that the heat is caused internally and only in the wanted tissues. Also,growth cells are more delicate than normal cells to hyperthermiatemperatures[110]. The use of IONPs to slaughtergrowth cells by hyperthermia hasremaineddescribed.
c. Mechanical movement: IONPs exposed to the oscillating magnetic field can also kill cancer cells in a non-heat mediated mechanism. IONPs labeled breast cancer MDA-MB-231 cells when exposed to oscillating gradients of a strong magnetic field showed damaging effects[26]. The destruction of cells was due to the aggregation and mechanical movement of IONPs.

IONPs Toxicity

Conflicting evidence regarding the toxicity of IONPs has been reported in vitro and in vivo studies. Factors inherent to nanosystems involving IONPs tend to directly interfere with their toxicity[111]. For instance, changes in nanoparticle size and shape were shown to play an important role in cell toxicity, with rod-shaped or nano-sized IONPs being more toxic than sphere-shaped and micrometric particles, respectively. The configuration of the nanosystem can also influence IONPs toxicity[111, 112]. A Janus microsphere encapsulating mesenchymal stem cells (MSC) and IONPs in two different compartments were proven to facilitate the magnetization and movement of the microspheres (due to the higher load capacity of IONPs), and to reduce cell toxicity, since the IONPs' derived toxic chemicals were isolated from the MSC compartment[113]. Furthermore, the surface charge of IONPs may affect cell cytotoxicity and genotoxicity. Positively charged IONPs were shown to be more toxic, since they undergo nonspecific interactions and adsorptive endocytosis with the negatively charged cell membrane, thus increasing their intracellular accumulation and affecting cell membrane integrity[114, 115].

Mechanisms of IONPs Toxicity

The toxicity of IONPs for different cell lines may be partially explained by the production of ROS, which has caused cellular oxidative stress[116]. When uptaken by cells via endocytosis, IONPs tend to accumulate in the lysosomes and are degraded in iron ions[117](Figure 11). In theory, the ions could cross the membranes and reach regions such as the cell nucleus and mitochondria, reacting with hydrogen peroxide and oxygen, thus generating ROS(Figure 11).

Despite oxidative stress is the most well-studied hypothesis of toxicity and cell damage, iron overload caused by exposure to IONPs can also generate serious deleterious effects and lead to cell death[118]. On the other hand, magnetite was shown to be responsible for increasing the level of lipid peroxidation and decreasing antioxidant enzymes of human lung alveolar epithelial cells (A-549), displaying concentration-dependent toxicity in vitro[111, 119]. Besides, a high dose of IONPs (with consequent iron excess) promoted elevated lipid metabolism, breakage of iron homeostasis, and exacerbated the loss of liver functions, being considered a risk factor for cirrhosis in a mice-model study.

Conclusions and Perspectives

Microorganisms resistant to conventional treatments evolve faster than the creation of new drugs and antibiotics[120]. Within this context, IONPs bear great potential for use in nano systems capable of overcoming the physical barriers of the microbial biofilm matrix in delivering the drugs directly to the target[111]. The next steps consist of further exploring the magnetic properties of IONPs to improve the drug effect using lower concentrations, thus reducing side effects and toxicity[121]. The various methods of synthesis have allowed the creation of nanoparticles with different sizes, structures, dispersions, and surface modifications. However, as wide variations have been reported among different research protocols, a direct comparison of the results obtained cannot be done[122]. This aspect points out the need for a refinement/standardization of protocols of synthesis and functionalization before to in vivo testing, aiming to produce nanoparticles with adequate stability, size-control, biocompatibility, and bioavailability[111]. Despite the growing body of scientific evidence on the use of IONPs in drug delivery systems, not all relevant drugs of medical/dental interest have been investigated, either alone or in combination with IONPs[123]. In this sense, the conception of novel IONPs-based nano systems able to carry multiple drugs simultaneously and with adequate release control on the target tissues could be beneficial in several clinical situations[123, 124]. These include the prevention/control of diseases associated with multiple microorganisms (e.g., bacteria and fungi), as well as conditions that require different categories of drugs (e.g., anti-inflammatory, antibiotics, and antifungal). Finally, regarding the applicability of IONPs-based nano systems, most of the clinical trials conducted so far have focused on MRI, so that clinical assessment of applications other than MRI is expected in the near future. For such purpose, large and industrial-scale production of IONPs-based nano systems is an important challenge to be overcome[125].

Future prospective

By implementing new biocompatible polymers, future studies should focus on correcting existing flaws in multimodal and multi Functional image processing probes. Finally, multi modal-multifunctional approaches may in the coming years boost clinical theranostics[126].A further key obstacle in biomedical research is the plausibility and reliability of producing largescale, multifunctional SPIO nanomaterials. Standardization and scalable manufacturing of SPIO nanoparticles persist issues for clinical development and marketing. Despite these obstacles, SPIof nanoparticles of the next generation carry enormous potential for personalized medicine[127].In regards, in terms of organic and/or inorganic SPIObased hybrid nanofluids, some number of nanomaterials (e.g. pure organic nanoparticles) is also used intensively for melanoma therapeutics, which includes drug delivery, PTT, PDT, fluorescence imaging and photo acoustic imaging, which will motivate more potential for future study. Intense interdisciplinary nanotechnology crossing research, In the end, component sciences, molecular genetics, and medicinal chemistry together with a related to clinical translation will bring tangible benefits for our patients[128, 129].



Figure 1, Schematic representation of anatomy of breast



Figure 2, Examining the Pathogenesis of Breast Cancer Using a Novel Agent-Based Model of Mammary Ductal Epithelium Dynamics



Figure. 3 Applications of iron oxide nanoparticles in health and medicine



Figure. 4, Physiochemical Consideration of Superparamagnetic Iron Oxide Nanoparticles)



Figure 5, Iron Oxide Nanoparticles for breast Cancer





Figure 6, Synthesis of iron oxide nanoparticles by three different methods (Physical, Chemical & Biological)



Figure 7, Progress in electrochemical synthesis of magnetic iron oxide nanoparticles



Figure 8, Many strategies and their subsequent application of IONPs



Figure 9. Schematic illustration of the main shells for the functionalization of iron oxide nanoparticles (IONPs). Grey circles represent the core of IONPs



Figure 10. Schematic illustration of drugs directly bound to iron oxide nanoparticles (IONPs) or to core-shell nano systems



Figure 11, Main mechanisms of action by which systems based on iron oxide nanoparticles (IONPs) generate cell toxicity. ROS: reactive oxygen species.



Nanocarriers of therapeutics

Table 1, IONPs in hyperthermia mediated cancer therapy

Nanoparticles	Cancer cell Lines	Observed effects
Starch coated MNPs	CRL-1666 cells and CRL- tumor xenografts in female Fischer rats	Effective ablation of metastatic tumors in the spine
Carboxymethyl dextran Coated IONPs	MCF-7 Cells	Magnetic fluid hyperthermia using IO-CMDX was more effective in killing the cancer cells than hot

		water hyperthermia
Superparamagnetic and ferromagnetic magnetite NPs	MCF-7 Cells	Greater healing and cell killing capacity of ferromagnetic NPs compared to superparamagnetic NPs with the same uptake
Uncoated IONPs (Bionized nano ferrite nanoparticles)	Female C3H mice bearing MTGB Tumors	MNP induced hyperthermia caused slower tumor regrowth in mice with reduced normal tissue damage compared to 915 MHz microwave hyperthermia at the same thermal dose
Dextran Coated MNPs	Murine breast adenocarcinoma (MTG-B) tumor-bearing C3H/He mice	Combination treatment of hyperthermia and radiation more effective in tumor growth suppression. MNP hyperthermia more effective than microwave mediated hyperthermia

Table2, Summary comparison of the synthetic methods for producing magnetic IONPs.

Methods	Rxn&Condition	Rxn Tem.	Shape Control	Yield
Co-precipitation	Very simple, ambient	20–150	Not good	High/scalable
Thermal decomposition	Complicated, insert atmosphere	100–350	Very good	High/scalable
Hydro- or solvothermal synthesis	Simple, high pressure	150–220	Very good	High/scalable
Sol-gel and polyol method	Complicated, ambient	25–200	Good	Medium
Microemulsion	Complicated, ambient	20–80	Good	Low
Sonolysis or sonochemical method	Very simple, ambient	20–50	Bad	Medium
Microwave-assisted synthesis	Very simple, ambient	100–200	Good	Medium
Biosynthesis	Complicated, ambient	Room temp.	Bad	Low
Electrochemical methods	Complicated, ambient	Room temp.	Medium	Medium
Aerosol/vapor methods	Complicated, insert atmosphere	>100	Medium	High/scalable

S.N.	Abbreviation	Full Forms
1	ANP	Atrial natriuretic peptide
2	AU	Gold
3	AG	Silver
4	BALB/C	Bagg albino
5	BRCA	Breast cancer

6	CTX	Chlorotoxin
7	CRL	Crown rump length
8	CAM	Complementary and alternative medicine
9	DNA	Deoxyribonucleic acid
10	DOX	Doxorubicin
11	EGFR	Epidermal growth factor receptor
11	EPR	Enhanced permeability & retention
12	EB	Epidermolysis bullosa
13	HER-2	Human epidermal factor receptor2
14	HSA	Hepatocyte specific antigen
15	IONPs	Iron oxide nanoparticles
16	MNPs	Magnetic nanoparticles
17	MCF	One thousand-cubic feet
18	MHT	Magnetic hyperthermia therapy
19	MPA	Mycophenolic acid
20	MRI	Magnetic resonance imaging
21	MSC	Mesenchymal stem cells
22	NPs	Nanoparticles
23	NYS	Nystatin
24	PTT	Partial thermoplastic time
25	PDT	Photo dynamic therapy
26	PSMA	Photo dynamic therapy
27	PEG	Prostate specific membrane antigen
28	PR	Progesterone receptor
29	RNA	Ribonucleic acid
30	RNS	Responsive neuro stimulation
31	ROS	Reactive oxygen species
32	RIT	Radioimmunotherapy
33	SPIONs	Super paramagnetic iron oxide nanoparticles
34	SST	Somatostatin
35	SIRNA	Small/short interfering RNA
36	TMX	Tamoxifen
37	TN	Triple-negative
38	VEGER	Vascular epidermal growth receptor
39	XRD	X-ray diffraction

References

1. Gale, T., *Electricity, Or Ethereal Fire, Considered: 1st. Naturally, as the Agent of Animal and Vegetable Life: 2d. Astronomically, Or as the Agent of Gravitation and Motion: 3d. Medically, Or Its Artificial Use in Diseases: Comprehending Both the Theory and Practice of Medical Electricity: and Demonstrated to be an Infallible Cure of Fever, Inflammation, and Many Other Diseases: Constituting the Best Family Physician Ever Extant*. 1802: Moffitt & Lyon.
2. McCracken, M., et al., *Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and*

Japanese ethnicities. CA: a cancer journal for clinicians, 2007. 57(4): p. 190-205.
3. Gown, A.M., *Current issues in ER and HER2 testing by IHC in breast cancer.* Modern pathology, 2008. 21(2): p. S8-S15.
4. Kim, D., et al., *Synthesis and biomedical applications of multifunctional nanoparticles.* Advanced Materials, 2018. 30(49): p. 1802309.
5. An, K. and G.A. Somorjai, *Size and shape control of metal nanoparticles for reaction selectivity in catalysis.* ChemCatChem, 2012. 4(10): p. 1512-1524.
6. Ponnamma, D., et al., *Synthesis, optimization and applications of ZnO/polymer nanocomposites.* Materials Science and Engineering: C, 2019. 98: p. 1210-1240.
7. Pelaz, B., et al., *Surface functionalization of nanoparticles with polyethylene glycol: effects on protein adsorption and cellular uptake.* ACS nano, 2015. 9(7): p. 6996-7008.
8. Tanaka, T., et al., *Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).* International journal of pharmaceutics, 2004. 277(1-2): p. 39-61.
9. Maeda, H., *Enhanced permeability and retention (epr) efect: Basis for drug targeting to tumor*, in *Biomedical aspects of drug targeting*. 2002, Springer. p. 211-228.
10. Meng, H., et al., *Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.* ACS nano, 2010. 4(8): p. 4539-4550.
11. Hassiotou, F. and D. Geddes, *Anatomy of the human mammary gland: Current status of knowledge.* Clinical anatomy, 2013. 26(1): p. 29-48.
12. Geddes, D.T., *The anatomy of the lactating breast: latest research and clinical implications.* Infant, 2007. 3(2): p. 59-63.
13. de la Pared Torácica, A. and A. y Mama, *Anatomy of the thoracic wall, axilla and breast.* Int. J. Morphol, 2006. 24(4): p. 691-704.
14. Jones, R.E. and K.H. Lopez, *Human reproductive biology*. 2013: Academic Press.
15. Heffner, L.J. and D.J. Schust, *The reproductive system at a glance*. Vol. 23. 2010: John Wiley & Sons.
16. Burlington, K. and M. Arts, *Strong Joints Forever.* 2009.
17. Lee, B.J. and F.E. Adair, *Traumatic fat necrosis of the female breast and its differentiation from carcinoma.* Annals of Surgery, 1924. 80(5): p. 670.
18. Harding, F., *Breast cancer: cause, prevention, cure*. 2006: Tekline publishing.
19. Pires, M.M., *Basal-like breast cancer: modeling its initiation and characterizing novel EGFR variants*. 2012, Columbia University.
20. Hartman, J., *Antiproliferative action of estrogen receptor beta and Hes-1 in breast cancer*. 2008: Biovetenskaper och näringslära/Biosciences and Nutrition.
21. Lakhani, S.R., et al., *The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.* Journal of clinical oncology, 2002. 20(9): p. 2310-2318.
22. Dykxhoorn, D.M., et al., *miR-200 enhances mouse breast cancer cell colonization to form distant metastases.* PloS one, 2009. 4(9): p. e7181.

23. Walsh, T., et al., *Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.* Jama, 2006. 295(12): p. 1379-1388.
24. Pedersen, B.K. and L. Hoffman-Goetz, *Exercise and the immune system: regulation, integration, and adaptation.* Physiological reviews, 2000.
25. Garg, A.D., et al., *Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation.* Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2010. 1805(1): p. 53-71.
26. Thoidingjam, S. and A.B. Tiku, *New developments in breast cancer therapy: role of iron oxide nanoparticles.* Advances in Natural Sciences: Nanoscience and Nanotechnology, 2017. 8(2): p. 023002.
27. Hu, W., *High moment synthetic magnetic nanoparticles for biomedical applications*. 2009: Stanford University.
28. Janousek, S., et al., *Nanoparticles in health and disease: an overview of nanomaterial hazard, benefit and impact on public health policy-current state and outlook.* Front Clin Drug Res Hematol, 2015. 2: p. 176.
29. Mushtaq, T., et al., *Synergistic ameliorative effect of iron oxide nanoparticles and Bacillus subtilis S4 against arsenic toxicity in Cucurbita moschata: polyamines, antioxidants, and physiochemical studies.* International journal of phytoremediation, 2020: p. 1-12.
30. Park, J., *Development of Magnetic Labels for Magnetic Immunoassays: Towards Multiplexed Detection of Pancreatic Cancer Markers Using Giant-Magnetoresistive Sensor*. 2017, The University of Utah.
31. JONES, O.G., *Protein nanostructures*, in *Edible nanostructures: A bottom-up approach*. 2014, Royal Society of Chemistry Cambridge. p. 69-113.
32. Goya, G., V. Grazu, and M.R. Ibarra, *Magnetic nanoparticles for cancer therapy.* Current nanoscience, 2008. 4(1): p. 1-16.
33. Couto, D., et al., *Iron oxide nanoparticles: An insight into their biomedical applications.* Current Medicinal Chemistry, 2015. 22(15): p. 1808-1828.
34. Ansari, S.A.M.K., et al., *Magnetic iron oxide nanoparticles: synthesis, characterization and functionalization for biomedical applications in the central nervous system.* Materials, 2019. 12(3): p. 465.
35. Vallabani, N.V., S. Singh, and A.S. Karakoti, *Magnetic nanoparticles: current trends and future aspects in diagnostics and nanomedicine.* Current drug metabolism, 2019. 20(6): p. 457-472.
36. LaGrow, A.P. and M.O. Besenhard, *6 Experimental Considerations for Scalable Magnetic Nanoparticle Synthesis and Surface Functionalization for Clinical Applications*. Clinical Applications of Magnetic Nanoparticles, 2018.
37. Vogelstein, B. and K.W. Kinzler, *Cancer genes and the pathways they control.* Nature medicine, 2004. 10(8): p. 789-799.
38. Shachar, S.S., et al., *Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy.* Clinical Cancer Research, 2017. 23(3): p. 658-665.
39. Bagnyukova, T.V., et al., *Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?* Cancer biology & therapy, 2010. 10(9): p. 839-853.
40. Reslan, L., *Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia*. 2010.
41. Dukes, M., *Sex hormones and related compounds, including hormonal contraceptives*, in *Side Effects of Drugs Annual*. 2011, Elsevier. p. 851-880.

42. Waks, A.G. and E.P. Winer, *Breast cancer treatment: a review.* Jama, 2019. 321(3): p. 288-300.
43. Bentzen, S.M., *Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.* Nature Reviews Cancer, 2006. 6(9): p. 702-713.
44. Deepak, P., et al., *Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma.* Journal of Drug Delivery Science and Technology, 2020: p. 101837.
45. Baronzio, G.F. and E.D. Hager, *Hyperthermia in cancer treatment: a primer*. 2008: Springer Science & Business Media.
46. Hola, K., et al., *Tailored functionalization of iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of biosubstances.* Biotechnology advances, 2015. 33(6): p. 1162-1176.
47. Sharma, S., et al., *Nanoparticles-based magnetic and photo induced hyperthermia for cancer treatment.* Nano Today, 2019. 29: p. 100795.
48. Baek, S., et al., *Smart multifunctional drug delivery towards anticancer therapy harmonized in mesoporous nanoparticles.* Nanoscale, 2015. 7(34): p. 14191-14216.
49. Yu, M.K., J. Park, and S. Jon, *Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy.* Theranostics, 2012. 2(1): p. 3.
50. Joseph, S., *Personality disorders: New symptom-focused drug therapy*. 1997: Psychology Press.
51. Vogel, J.M., *Tunnel vision: The regulation of endocrine disruptors.* Policy Sciences, 2004. 37(3-4): p. 277-303.
52. Barry Blackwell, M. and M.P. Lond, *Treating the Brain: An Odyssey.*
53. Estevanato, L.L., et al., *Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy.* International Journal of Nanomedicine, 2012. 7: p. 5287.
54. Ksiazek, I., et al., *Toxicity studies of selol—An organic selenium (iv) compound-in vitro research.* Int. J. Pharm. Pharm. Sci, 2014. 6(5).
55. Gao, J., et al., *The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.* Biomaterials, 2011. 32(13): p. 3459-3470.
56. Sandiford, L., et al., *Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging.* Acs Nano, 2013. 7(1): p. 500-512.
57. Hitchens, T.K., et al., *Combining perfluorocarbon and superparamagnetic iron-oxide cell labeling for improved and expanded applications of cellular MRI.* Magnetic resonance in medicine, 2015. 73(1): p. 367-375.
58. Zhu, Y., et al., *In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles.* International journal of molecular sciences, 2015. 16(5): p. 9573-9587.
59. McLatchie, G., N. Borley, and J. Chikwe, *Oxford handbook of clinical surgery*. 2013: OUP Oxford.
60. Welcome, M.O., *Gastrointestinal Physiology*. 2018: Springer.
61. Wu, W., et al., *Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications.* Science and technology of advanced materials, 2015.

62. Tombácz, E., et al., *Magnetic iron oxide nanoparticles: Recent trends in design and synthesis of magnetoresponsive nanosystems.* Biochemical and biophysical research communications, 2015. 468(3): p. 442-453.
63. Rüdiger, S., U. Gross, and E. Kemnitz, *Non-aqueous sol–gel synthesis of nano-structured metal fluorides.* Journal of Fluorine Chemistry, 2007. 128(4): p. 353-368.
64. Bonvin, D., et al., *Tuning properties of iron oxide nanoparticles in aqueous synthesis without ligands to improve MRI relaxivity and SAR.* Nanomaterials, 2017. 7(8): p. 225.
65. Niraula, G., et al., *Liquid-Phase Synthesis of Multifunctional Nanomaterials: A Recent Update*, in *Magnetic Nanoheterostructures*. 2020, Springer. p. 1-56.
66. Leslie-Pelecky, D.L. and R.D. Rieke, *Magnetic properties of nanostructured materials.* Chemistry of materials, 1996. 8(8): p. 1770-1783.
67. Ahmed, I., et al., *The Importance of Iron oxides in Natural Environment and Significance of its Nanoparticles Application.* Nanomaterials for Environmental Applications and their Fascinating Attributes, 2018. 2: p. 218.
68. Hufschmid, R., et al., *Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition.* Nanoscale, 2015. 7(25): p. 11142-11154.
69. Salavati-Niasari, M. and F. Davar, *Synthesis of copper and copper (I) oxide nanoparticles by thermal decomposition of a new precursor.* Materials Letters, 2009. 63(3-4): p. 441-443.
70. Salek-Maghsoudi, A., et al., *Recent advances in biosensor technology in assessment of early diabetes biomarkers.* Biosensors and Bioelectronics, 2018. 99: p. 122-135.
71. Wacks, R., *Privacy: A very short introduction*. 2015: OUP Oxford.
72. Prabha, G. and V. Raj, *Synthesis and characterization of chitosan–polyvinylpyrrolidone–bovine serum albumin-coated magnetic iron oxide nanoparticles as potential carrier for delivery of tamoxifen.* Journal of the Iranian Chemical Society, 2018. 15(4): p. 871-884.
73. He, S., et al., *Crucial breakthrough of second near-infrared biological window fluorophores: design and synthesis toward multimodal imaging and theranostics.* Chemical Society Reviews, 2018. 47(12): p. 4258-4278.
74. Thanh, N.T. and L.A. Green, *Functionalisation of nanoparticles for biomedical applications.* Nano Today, 2010. 5(3): p. 213-230.
75. Magro, M., et al., *Triggering mechanism for DNA electrical conductivity: reversible electron transfer between DNA and iron oxide nanoparticles.* Advanced Functional Materials, 2015. 25(12): p. 1822-1831.
76. Karakatsanis, A., et al., *Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer.* British Journal of Surgery, 2017. 104(12): p. 1675-1685.
77. Kim, D.-K., et al., *Superparamagnetic iron oxide nanoparticles for bio-medical applications.* Scripta materialia, 2001. 44(8-9): p. 1713-1717.
78. Tanaka, S., et al., *A Review on Iron Oxide-Based Nanoarchitectures for Biomedical, Energy Storage, and Environmental Applications.* Small Methods, 2019. 3(5): p. 1800512.
79. Petros, R.A. and J.M. DeSimone, *Strategies in the design of nanoparticles for therapeutic applications.* Nature reviews Drug discovery, 2010. 9(8): p. 615-627.

80. Athar, M. and A.J. Das, *Therapeutic nanoparticles: State-of-the-art of nanomedicine.* Adv. Mater. Rev, 2014. 1(1): p. 25-37.
81. Antonelli, A. and M. Magnani, *Red blood cells as carriers of iron oxide-based contrast agents for diagnostic applications.* Journal of biomedical nanotechnology, 2014. 10(9): p. 1732-1750.
82. El-Boubbou, K., *Magnetic iron oxide nanoparticles as drug carriers: preparation, conjugation and delivery.* Nanomedicine, 2018. 13(8): p. 929-952.
83. Marcee, A.K., *Expanded access to Phase II clinical trials in oncology: a step toward increasing scientific validity and compassion.* Food and drug law journal, 2008. 63(2): p. 439-457.
84. Yang, X., et al., *cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging.* Biomaterials, 2011. 32(17): p. 4151-4160.
85. Schleich, N., et al., *Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging.* International journal of pharmaceutics, 2013. 447(1-2): p. 94-101.
86. Shkilnyy, A., et al., *Synthesis and evaluation of novel biocompatible super-paramagnetic iron oxide nanoparticles as magnetic anticancer drug carrier and fluorescence active label.* The Journal of Physical Chemistry C, 2010. 114(13): p. 5850-5858.
87. Yang, Y., et al., *Doxorubicin-conjugated heparin-coated superparamagnetic iron oxide nanoparticles for combined anticancer drug delivery and magnetic resonance imaging.* Journal of biomedical nanotechnology, 2016. 12(11): p. 1963-1974.
88. Hwang, J., et al., *Effective delivery of immunosuppressive drug molecules by silica coated iron oxide nanoparticles.* Colloids and Surfaces B: Biointerfaces, 2016. 142: p. 290-296.
89. Ngobili, T.A. and M.A. Daniele, *Nanoparticles and direct immunosuppression.* Experimental Biology and Medicine, 2016. 241(10): p. 1064-1073.
90. Kauffman, K.J., et al., *Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression.* International journal of pharmaceutics, 2012. 422(1-2): p. 356-363.
91. Vaghela, R., et al., *Recent advances in nanosystems and strategies for managing leishmaniasis.* Current drug targets, 2017. 18(14): p. 1598-1621.
92. Cho, S.-J., et al., *Zebrafish as an animal model in epilepsy studies with multichannel EEG recordings.* Scientific reports, 2017. 7(1): p. 1-10.
93. Oghabian, M., et al., *Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI.* Journal of nanoscience and nanotechnology, 2011. 11(6): p. 5340-5344.
94. Artemov, D., et al., *MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.* Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine, 2003. 49(3): p. 403-408.
95. Durmus, N.G., et al., *Enhanced efficacy of superparamagnetic iron oxide nanoparticles against antibiotic-resistant biofilms in the presence of metabolites.* Advanced materials, 2013. 25(40): p. 5706-5713.
96. Taylor, E.N., et al., *Superparamagnetic iron oxide nanoparticles (SPION) for the treatment of antibiotic-resistant biofilms.* Small, 2012. 8(19): p. 3016-3027.

97. Istrate, C.M., et al., *Iron oxide nanoparticles modulate the interaction of different antibiotics with cellular membranes.* Rom. J. Morphol. Embryol, 2014. 55(3): p. 849-56.
98. Parveen, S., et al., *Preparation, characterization and antifungal activity of iron oxide nanoparticles.* Microbial pathogenesis, 2018. 115: p. 287-292.
99. Prucek, R., et al., *The targeted antibacterial and antifungal properties of magnetic nanocomposite of iron oxide and silver nanoparticles.* Biomaterials, 2011. 32(21): p. 4704-4713.
100. Gupta, A.K. and M. Gupta, *Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications.* biomaterials, 2005. 26(18): p. 3995-4021.
101. Rowley, T.F. and A. Al-Shamkhani, *Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo.* The Journal of Immunology, 2004. 172(10): p. 6039-6046.
102. Gupta, A.K., et al., *Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications.* 2007.
103. Amstad, E., M. Textor, and E. Reimhult, *Stabilization and functionalization of iron oxide nanoparticles for biomedical applications.* Nanoscale, 2011. 3(7): p. 2819-2843.
104. Silva, A.C., et al., *Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment.* International journal of nanomedicine, 2011. 6: p. 591.
105. Espinosa, A., et al., *Duality of iron oxide nanoparticles in cancer therapy: amplification of heating efficiency by magnetic hyperthermia and photothermal bimodal treatment.* ACS nano, 2016. 10(2): p. 2436-2446.
106. Gill, S.S. and N. Tuteja, *Reactive oxygen species and antioxidant machinery in abiotic stress tolerance in crop plants.* Plant physiology and biochemistry, 2010. 48(12): p. 909-930.
107. Manton, K.G., S. Volovik, and A. Kulminski, *ROS effects on neurodegeneration in Alzheimer's disease and related disorders: on environmental stresses of ionizing radiation.* Current Alzheimer Research, 2004. 1(4): p. 277-293.
108. Abdal Dayem, A., et al., *The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles.* International journal of molecular sciences, 2017. 18(1): p. 120.
109. Lim, E.-K., et al., *Nanomaterials for theranostics: recent advances and future challenges.* Chemical reviews, 2015. 115(1): p. 327-394.
110. Bhuyan, B.K., et al., *Sensitivity of different cell lines and of different phases in the cell cycle to hyperthermia.* Cancer research, 1977. 37(10): p. 3780-3784.
111. Arias, L.S., et al., *Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity.* Antibiotics, 2018. 7(2): p. 46.
112. Joris, F., et al., *Assessing nanoparticle toxicity in cell-based assays: influence of cell culture parameters and optimized models for bridging the in vitro–in vivo gap.* Chemical Society Reviews, 2013. 42(21): p. 8339-8359.
113. Thomas, R.G., et al., *Electromagnetic manipulation enabled calcium alginate Janus microsphere for targeted delivery of mesenchymal stem cells.* International Journal of Biological Macromolecules, 2018. 110: p. 465-471.

114. Reddy, L.H., et al., *Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications.* Chemical reviews, 2012. 112(11): p. 5818-5878.
115. Deng, J. and C. Gao, *Recent advances in interactions of designed nanoparticles and cells with respect to cellular uptake, intracellular fate, degradation and cytotoxicity.* Nanotechnology, 2016. 27(41): p. 412002.
116. Soenen, S.J., et al., *Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation.* Nano today, 2011. 6(5): p. 446-465.
117. Feng, Q., et al., *Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings.* Scientific reports, 2018. 8(1): p. 1-13.
118. Sabareeswaran, A., *Cellular and molecular effects of surface modified magnetic nanoparticles in Rat model.* 2015, SCTIMST.
119. da Silva, P.B., et al., *Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action-Review.* Current medicinal chemistry, 2019. 26(12): p. 2108-2146.
120. Levin-Reisman, I., et al., *Antibiotic tolerance facilitates the evolution of resistance.* Science, 2017. 355(6327): p. 826-830.
121. Alegret, N., A. Criado, and M. Prato, *Recent advances of graphene-based hybrids with magnetic nanoparticles for biomedical applications.* Current medicinal chemistry, 2017. 24(5): p. 529-536.
122. Jansen, J.P., et al., *Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.* Value in health, 2011. 14(4): p. 417-428.
123. Wigger, H., *Current and future product applications of iron oxide and silver nanoparticles*, in *Environmental Release of and Exposure to Iron Oxide and Silver Nanoparticles*. 2017, Springer. p. 89-146.
124. de Sousa Cunha, F., et al., *Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics.* Journal of Drug Targeting, 2019. 27(7): p. 732-741.
125. Basuki, J.S., *Multi-functionalization of Iron Oxide Nanoparticles for Chemotherapeutic Delivery and Magnetic Resonance Imaging Contrast Applications*. 2014, University of New South Wales, Australia.
126. Sanavio, B., *Therapeutic Benefits from Nanoparticles.* 21st Century Nanoscience–A Handbook: Nanopharmaceuticals, Nanomedicine, and Food Nanoscience (Volume Eight), 2020.
127. Morris, S., *The future of netcrime now: Part 1–threats and challenges.* Home Office Crime and Policing Group, Washington DC, USA, Tech. Rep, 2004. 62(04).
128. Lu, H., et al., *Translational research and therapeutic applications of stem cell transplantation in periodontal regenerative medicine.* Cell transplantation, 2013. 22(2): p. 205-229.
129. Tibbals, H.F., *Medical nanotechnology and nanomedicine*. 2017: Crc Press.
130. FA: Hersh F. Mahmood, Hooshang Dabbagh, Azad A. Mohammed, Comparative study on using chemical and natural admixtures (grape and mulberry extracts) for concrete, Case Studies in Construction Materials, Volume 15, 2021,

131. Kumar, S. (2022). A quest for sustainium (sustainability Premium): review of sustainable bonds. Academy of Accounting and Financial Studies Journal, Vol. 26, no.2, pp. 1-18
132. Allugunti, V.R. (2019). Diabetes Kaggle Dataset Adequacy Scrutiny using Factor Exploration and Correlation. International Journal of Recent Technology and Engineering, Volume-8, Issue-1S4, pp 1105-1110.